Novartis AG ADR (NVS)vsPTC Therapeutics Inc (PTCT)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
PTCT
PTC Therapeutics Inc
$65.06
+0.79%
HEALTHCARE · Cap: $5.83B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 3169% more annual revenue ($56.58B vs $1.73B). PTCT leads profitability with a 39.4% profit margin vs 23.9%. PTCT appears more attractively valued with a PEG of 0.81. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PTCT
Hold45
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+20.8%
Fair Value
$89.55
Current Price
$65.06
$24.49 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Attractively priced relative to earnings
Keeps 39 of every $100 in revenue as profit
Growing faster than its price suggests
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
ROE of -7740.0% — below average capital efficiency
Revenue declined 22.7%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PTCT
The strongest argument for PTCT centers on P/E Ratio, Profit Margin, PEG Ratio. Profitability is solid with margins at 39.4% and operating margin at -49.6%. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : PTCT
The primary concerns for PTCT are EPS Growth, Return on Equity, Revenue Growth.
Key Dynamics to Monitor
PTCT carries more volatility with a beta of 0.55 — expect wider price swings.
NVS is growing revenue faster at -0.7% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
NVS scores higher overall (51/100 vs 45/100), backed by strong 23.9% margins. PTCT offers better value entry with a 20.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →PTC Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders. The company is headquartered in South Plainfield, New Jersey.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?